Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Also Sees Chance To Challenge Hemlibra
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.
